

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.

艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

**VOLUNTARY ANNOUNCEMENT
OFFICIAL APPLICATION FOR CLINICAL TRIALS FOR
ABSORBED TETANUS VACCINE SUBMITTED**

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company of the latest business developments of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the official application for clinical trials for the Group’s absorbed tetanus vaccine has been submitted to the Center for Drug Evaluation (CDE) of National Medical Products Administration of China in August 2024. The research and development of the vaccine is in line with the Company’s strategic layout in product research and development and is an important step to realize the Company’s research and development of multidisease and multivalent products, which will further improve the Company’s product pipelines, help the Company consolidate its industry position in the field of vaccines not covered by the immunization programs (Class II vaccine) in China, and contribute to the sustainable development of the Company’s vaccine business.

Tetanus is an extremely serious and potentially fatal disease, and tetanus vaccination is currently the most cost-effective and effective measure to prevent it. In addition, the Group is actively promoting the research and development of diphtheria, tetanus and acellular pertussis – HIB combined vaccine (the “**Tetravaccine**”), and is expected to successively submit clinical trial applications for Tetravaccine and its component vaccines from 2024. The Tetravaccine is used to prevent invasive infections caused by pertussis, diphtheria, tetanus and Haemophilus Influenzae type b, and has the advantages of reducing the number of vaccinations for infants and young children, and enhancing the vaccination compliance of parents, infants and young children. Multidisease vaccine is the development trend of the industry. According to the data of China

Insights Industry Consultancy Limited, an industry consultant, the Chinese market size of the multidisease vaccine reached RMB6.457 billion in 2022, and is expected to reach RMB9.572 billion in 2030, which provides strong support for the strengthening of the Company's core competitiveness, enhancement of the Company's market position, and the Company's sustainable and steady development.

By order of the Board
AIM Vaccine Co., Ltd.
Mr. Yan ZHOU
*Chairman of the Board, Executive Director
and Chief Executive Officer*

Hong Kong, August 29, 2024

As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Wen GUAN, Mr. Shaojun JIA and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Hui OUYANG, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.